Expanding drug access in Brazil: Lessons for Latin America and Canada

Canadian Journal of Public Health

Volumn 97, Issue 6, 2006, Pages

  Cohen, Jillian Clare ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Brazil; Canada; Drug access; Essential medicines; TRIPS Agreement

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ESSENTIAL DRUG; GENERIC DRUG; NELFINAVIR;

ARTICLE; BRAZIL; CANADA; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL COOPERATION; INTERNATIONAL RELATIONS; PATENT; PUBLIC HEALTH; SOCIAL MEDICINE; COMMERCIAL PHENOMENA; DRUG LEGISLATION; ECONOMICS; HEALTH CARE DELIVERY; HEALTH SERVICES RESEARCH; HUMAN; LEGAL ASPECT; ORGANIZATION; POLICY; SOUTH AND CENTRAL AMERICA;

BRAZIL; CANADA; COMMERCE; DECISION MAKING, ORGANIZATIONAL; DRUG INDUSTRY; DRUGS, ESSENTIAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONALITY; LATIN AMERICA; LEGISLATION, DRUG; ORGANIZATIONAL CASE STUDIES; PATENTS; PUBLIC POLICY;

EID: 33845503932     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Canadian International Development Agency [Homepage on the Internet]. Gatineau: CIDA, 2004. Available online at: http://www.acdi-cida.gc.ca/ cidaweb/webcountry.nsf/vLUDocEn/A8778A5D9EF2B9E685256F54004DA5A3? OpenDocument (Accessed February 8, 2006).
2. Ministry of Health, Brazil. The Brazilian National Drug Policy, 2000.
3. Brasil. Ministério da Saúde. Política Nacional de Medicamentos. Brasília: Ministério da Saúde. 1999; 40.
4. Magãlhaes LCG, Tomich FA, Silveira FG, Vianna SW, Safatle L, de Oliveira AB, et al. Tributação e dispêndio com saúde das famílias brasileiras: Avaliação da carga tributária sobre medicamentos. 2001;24:21. Available online at: www.ipea.gov.br (Accessed August 5, 2003).
5. Lima-Costa MF, Barreto SM, Giatti L. Health status, physical functioning, health services utilization, and expenditures on medicines among Brazilian elderly: A descriptive study using data from the National Household Survey. Cad Saúde Pública 2003; 19(3):121.
6. Redwood H. Brazil: The Future Impact of Pharmaceutical Patents. Suffolk: Oldwicks Press Limited, 1995;59.
7. Pharmaceutical Research Manufacturers of America (PhRMA) 1987 petition to the United States Trade Representative (USTR).
8. Redwood H. New Horizons in India: The Consequences of Patent Protection. Suffolk: Oldwicks Press Limited, 1994;21.
9. Bermudez J, Epsztein R, Oliveira MA, Hasenclever L. The WTO Agreement and Patent Protection in Brazil: Recent Changes and Implications for Local Production and Access to Medicines. Rio de Janeiro: ENSP/WHO Oswaldo Cruz Foundation, 2000.
10. http://www.pharma.org/issues (Accessed February 8, 2006).
11. Buscaglia E, Long C. Hoover Institution Essays in Public Policy. U.S. Foreign Policy and Intellectual Property Rights in Latin America. Stanford, 2000;3.
12. World Trade Organization. U.S. Government Request for WTO consultations with Government of Brazil, 2000. Official document WT/DS199/1.
13. World Bank, Operations Evaluation Department. Brazil First and Second AIDS and STD Control Projects; Project Performance Assessment Report No. 28819, 2004;ix.
14. Médecins Sans Frontières. Six-Month Report Card: Have AIDS Drug Prices for the Poor Been Slashed? [Press Release on the Internet]. Geneva: MSF; 2000. Available online at: http://www. accessmed-msf.org./ prod/publications.asp?scntid=218200154494&contenttype=PARA& (Accessed February 8, 2003).
15. Cohen JC, Lybecker KM. AIDS Policy and Pharmaceutical Patents: Brazil's Strategy to Safeguard Public Health. The World Economy 2005;28(2):211.
16. Latin America: Healthcare and pharmaceuticals forecast. Economist Intelligence Unit news alert. 2004. Available online at: http://home.aigonline.com/content (Accessed February 8, 2006).